Roger S. Newton, PhD, FAHA

Dr. Newton has worked for more than 30 years in the pharmaceutical and life sciences industries. He is currently founder, President & CEO, and a director of Esperion Therapeutics, Inc. Dr. Newton was with Warner Lambert/Parke-Davis (now Pfizer) from 1981-1998. As a Distinguished Scientist and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed cholesterol-reducing drug in the world, atorvastatin (LipitorĀ®).

Dr. Newton is an Adjunct Associate Professor in the Department of Pharmacology at the University of Michigan Medical School. He has co-authored nearly one hundred peer-reviewed articles and chapters during his research career. Dr. Newton has a PhD in nutrition from the University of California, Davis, a Master of Science degree in nutritional biochemistry from the University of Connecticut, graduated with Honors in Biology from Lafayette College and did a post-doctoral fellowship in a Specialized Center of Research in Atherosclerosis at the University of California, San Diego in LaJolla.